Democrat-Controlled House Will Turn Up The Volume On Drug Pricing
With US House of Representatives now controlled by Democrats, lower chamber of Congress will likely increase hearings and investigations into industry pricing practices, but any legislation will probably need to dovetail with President Trump’s agenda to advance.
You may also be interested in...
Biopharma will continue to seek ways to pass legislation reducing the 70% discount in Medicare Part D coverage gap but it looks like industry's next chance will be after the November elections.
Even though measure was blocked in Congress, it may still advance through regulation.
Policy exempts indications covered by protected classes policy, including cancer treatments.